Abstract In 2011, the National Institute on Aging and Alzheimer's Association created
separate diagnostic recommendations for the preclinical, mild cognitive impairment, and …

We describe a recently recognized disease entity, limbic-predominant age-related TDP-43
encephalopathy (LATE). LATE neuropathological change (LATE-NC) is defined by a …

Introduction Our goal was to develop cut points for amyloid positron emission tomography
(PET), tau PET, flouro-deoxyglucose (FDG) PET, and MRI cortical thickness. Methods We …

Background A new classification for biomarkers in Alzheimer's disease and cognitive ageing
research is based on grou** the markers into three categories: amyloid deposition (A) …

In the 12 years since the publication of the first Consensus Paper of the WFSBP on
biomarkers of neurodegenerative dementias, enormous advancement has taken place in …

Large phenotypically diverse research cohorts with both amyloid and tau PET have only
recently come into existence. Our objective was to determine relationships between the …

Alzheimer's disease (AD) is a major cause of dementia, disability, and death in the elderly.
Despite recent advances in our understanding of the basic biological mechanisms …

Biomarkers have a key role in Alzheimer's disease (AD) drug development. Biomarkers can
assist in diagnosis, demonstrate target engagement, support disease modification, and …

Clinical trials with anti-tau drugs will need to target individuals at risk of accumulating tau.
Our objective was to identify variables available in a research setting that predict future rates …

Age-related cognitive impairment and dementia are an increasing societal burden.
Epidemiological studies indicate that lifestyle factors, eg physical, cognitive and social …